3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
987
Neoplasms
796
Carcinoma, Non-Small-Cell Lung
763
Prostatic Neoplasms
588
Colorectal Neoplasms
484
Lung Neoplasms
468
Neoplasm Metastasis
413
Multiple Myeloma
382
Leukemia, Myeloid, Acute
377
Ovarian Neoplasms
316
Pancreatic Neoplasms
297
Melanoma
278
Squamous Cell Carcinoma of Head and Neck
258
Recurrence
244
Carcinoma, Hepatocellular
240
Brain Neoplasms
226
Glioblastoma
217
Triple Negative Breast Neoplasms
204
Carcinoma, Renal Cell
200
Head and Neck Neoplasms
198
Lymphoma
193
Stomach Neoplasms
190
Precursor Cell Lymphoblastic Leukemia-Lymphoma
189
Sarcoma
172
Glioma
171
Uterine Cervical Neoplasms
169
Lymphoma, Non-Hodgkin
169
Endometrial Neoplasms
169
Lymphoma, Large B-Cell, Diffuse
166
Urinary Bladder Neoplasms
160
Interventions
pembrolizumab
1
Paclitaxel
1
Carboplatin
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Squamous Non-small Cell Lung Cancer
×
90 days
×
Clear all
NCT07221474
2026-05-26
INTerpath-13
Merck Sharp & Dohme LLC
Phase 2
Recruiting
180 enrolled